Press coverage about Avadel Pharmaceuticals (NASDAQ:AVDL) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Avadel Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.7820483764937 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of AVDL stock traded down $0.16 during trading hours on Friday, reaching $6.91. 616,892 shares of the company’s stock were exchanged, compared to its average volume of 291,318. The company has a market cap of $283.39, a PE ratio of 22.29 and a beta of 1.55. Avadel Pharmaceuticals has a fifty-two week low of $6.71 and a fifty-two week high of $11.93.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its quarterly earnings results on Thursday, March 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). The business had revenue of $34.20 million for the quarter, compared to analyst estimates of $34.16 million. Avadel Pharmaceuticals had a return on equity of 15.40% and a net margin of 38.64%. The firm’s revenue was down 20.6% compared to the same quarter last year. sell-side analysts forecast that Avadel Pharmaceuticals will post -1.29 earnings per share for the current year.

Avadel Pharmaceuticals declared that its Board of Directors has initiated a share repurchase program on Tuesday, March 27th that allows the company to buyback $7.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 2.7% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

A number of brokerages recently commented on AVDL. Roth Capital set a $14.00 price objective on shares of Avadel Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. BidaskClub downgraded Avadel Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. TheStreet downgraded Avadel Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Thursday, March 8th. Finally, Zacks Investment Research raised Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $20.00.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.

Insider Buying and Selling by Quarter for Avadel Pharmaceuticals (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.